Quaternary ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 4, 1998, Pages 319-326

  Civoli, Francesca ^a,b   Daniel, Larry W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Ether lipids; Leukemia cells; Protein kinase C

Indexed keywords

EDELFOSINE; ETHER LIPID; FATTY ACID DERIVATIVE; ILMOFOSINE; MILTEFOSINE; PROTEIN KINASE C; QUATERNARY AMMONIUM DERIVATIVE; SRI 62834;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; CYTOCHEMISTRY; CYTOTOXICITY; DRUG RESISTANCE; ENZYMATIC ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; DRUG RESISTANCE; ENZYME ACTIVATION; FURANS; HL-60 CELLS; HUMANS; PHOSPHOLIPID ETHERS; PHOSPHORYLCHOLINE; PROTEIN KINASE C; QUATERNARY AMMONIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRADECANOYLPHORBOL ACETATE;

EID: 0031875043     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050824     Document Type: Article

References (44)

1. Bazill GW, Dexter TM (1990) Role of endocytosis in the action of ether lipids on WEHI-3B, HL-60 and FCDP-mix A4 cells. Cancer Res 50: 7505-7512
2. Berdel WE, Andreesen R, Munder PG (1985). Synthetic alkylphospholipid analogs: a new class of antitumor agents. In: Kuo JF (ed) Phospholipids and cellular regulation, vol 2. CRC Press, Boca Raton, pp 41-73
3. Berdel WE, Vogler WR, Olson AC (1992) Alkyl-lysophospholipid purging for autologous bone marrow transplantation in acute leukemia in second or subsequent remission after extramedullary relapse. Progr Clin Biol Res 377: 79-85
4. Berggren MI, Gallegos A, Dressier LA, Modest EJ, Powis G (1993) Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res 53:4297-4302
5. Blumberg PM, Acs G, Areces LB, Kazanaietz MG, Lewing NE, Szallasi Z (1994) Protein kinase C in signal transduction and carcinogenesis. Progress in Clinical and Biological Research 387: 3-19
6. Blumberg PM, Acs G, Hannun YA (1994) Regulation of protein kinase C and its role in cancer biology. Cancer and Metastasis Rev 13: 411-431
7. Boggs K, Rock C, Jackowski S (1995) Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP:phosphocholine cytidylyltransferase step. J Biol Chem 270: 7757-7764
8. Boggs K, Rock C, Jackowski S (1995) Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. J Biol Chem 270: 11612-11618
9. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 72: 248-254
10. 3. Cancer Chemother Pharmacol 38: 269-272
11. Daniel LW (1991) Ether lipids in experimental cancer chemotherapy. In: Hickman JA, Tritton TR (eds) Cancer chemotherapy. Blackwell, Oxford, p 2-57
12. Daniel LW, Etkin LA, Morrison BT, Parker J, Morris-Natschke S, Surles JR, Piantadosi C (1987) Ether lipids inhibit the effects of phorbol diester tumor promoters. Lipids 22: 851-855
13. Daniel LW, Small GW, Schmitt JD (1988) Alkyl-linked diglycerides inhibit protein kinase C activation by diacylglycerols. Biophys Biochem Res Commun 151: 291-297
14. 3 inhibits nuclear factor-κB activation by 12-O-tetradecanoylphorbol-13-acetate but not by tumor necrosis factor-α or interleukin 1α. Cancer Res 55: 4844-4849
15. Gamard CJ, Blobe GC, Hannun YA, Obeid LM (1994) Specific role for protein kinase C beta in cell differentiation. Cell Growth Differ 5: 405-409
16. Glasser L, Somberg LB, Vogler WR (1984) Purging murine leukemic marrow with alkyllysophospholipids. Blood 64: 1288-1291
17. Gratas C, Powis G (1993) Inhibition of phospholipase D by agents that inhibit cell growth. Anticancer Res 13: 1239-1244
18. 2+-dependent protein phosphorylation system in various types of leukemia cells from human patients and in human leukemic cell lines HL-60 and K562, and its inhibition by alkyl-lysophospholipid. Cancer Res 43: 2955-2961
19. Herrmann DBJ, Neumann HA, Berdel WE, Heim ME, Fromm M, Boerner D, Bicker U (1988) Phase I trial of the thioether phospholipid analogue BM 41.440 in cancer patients. Lipids 11: 962-966
20. Hoffman DR, Hoffman LH, Snyder F. (1986) Cytotoxicity and metabolism of alkyl phospholipid analogs in neoplastic cells. Cancer Res 46: 5803-5809
21. Houlihan WJ, Lohmeyer M, Workman P, Cheon SH (1995) Phospholipid antitumor agents. Med Res Rev 15: 157-223
22. Koenigsmann MP, Notter M, Knauf WU, Papadimitriou CA, Oberg D, Reufi B, Mucke C, Thiel E, Berdel WE (1996) Chemopurging of peripheral blood-derived progenitor cells by alkyl-lysophospholipid and its effect on haematopoietic rescue after high-dose therapy. Bone Marrow Transplant 18: 549-557
23. Kötting J, Marschner NW, Neumuhller W, Unger C, Eibl H (1992) Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of activity, serum binding and tissue distribution. Progr Exp Tumor Res 31:131-142
24. Marasco CJ, Piantadosi C, Meyer KE, Morris-Natschke S, Ishaq K, Small GW, Daniel LW (1990) Synthesis and biological evaluation of novel quaternary ammonium derivatives of alkylglycerols as potent inhibitors of protein kinase C. J Med Chem 33: 985-992
25. Mehren M von, Giantonio BJ, McAleer C, Schilder R, McPhillips J, O'Dwyer PJ (1995) Phase I trial of ilmofosine as a 24 hour infusion weekly. Invest New Drugs 13: 205-210
26. 3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL. Cancer Res 57: 1320-1328
27. Parker J, Daniel LW, Waite M (1987) Evidence of protein kinase C involvement in phorbol diester-stimulated arachidonic acid release and prostaglandin synthesis. J Biol Chem 262: 5385-5393
28. Powis, G (1994) Signalling pathways as targets for anticancer drug design. Pharmacol Ther 62: 57-95
29. Powis G, Workman P (1994) Signalling targets for the development of cancer drugs. Anticancer Drug Des 9: 263-277
30. Principe P, Braquet P (1995) Advances in ether phospholipids treatment of cancer. Crit Rev Oncol 18: 155-178
31. Salari H, Dryden P, Davenport R, Howard S, Jones K, Bittman R (1992) Inhibition of protein kinase C by ether-linked lipids is not correlated with their antineoplastic activity on WEH1-3B and R6X-B15 cells. Biochim Biophys Acta 1134: 81-88.
32. Schick HD, Berdel WE, Fromm M, Fink U, Jehn U, Ulm K, Reichert A, Eibl H, Unger C, Rastetter J (1987) Cytotoxic effects of ether lipids and derivatives in human nonneoplastic hone marrow cells and leukemic cells in vitro. Lipids 22:904-910
33. 3. Lipids 30: 715-723
34. Storch J, Munder PG (1987) Increased membrane permeability for an untitumoral alkyl lysophospholipid in sensitive tumor cells. Lipids 22: 813-819
35. Surette ME, Winklerv JD, Fonteh AN, Chilton FH (1996) Relationship between arachidonale-phospholipid signalling and apoptosis. Biochemistry 35: 9187-9196
36. Tidwell T, Guzman G, Vogler WR (1981) The effects of alkyllysophospholipids on leukemic cell lines. I. Differential action on two human leukemic cell lines, HL-60 and K562. Blood 57: 794-797
37. Tonetti DA, Horio M, Collart FR, Huberman E (1992) Protein kinase C beta gene expression is associated with susceptibility of human promyelocytic leukemia cells to phorbol ester-induced differentiation. Cell Growth Differ 3: 739-745
38. Tonetti DA, Henning-Chubb C, Yamanishi DT, Huberman E (1994) Protein kinase C-beta is required for macrophage differentiation of human HL-60 leukemia cells. J Biol Chem 269: 23230-23235
39. Unger C, Eibl H, Breiser A, Heyden HW von, Engel J, Hilgard P, Sindermann H, Peukert M, Nagel GA (1988) Hexadecylphosphocholine (D18506) in the topical treatment of skin metastases: a phase-1 trial. Onkologie 11: 295-296
40. Verdonck LF, Heugten HG (1997) Ether lipids are effective cytotoxic drugs against multidrug-rcsistant acute leukemia cells and can act by the induction of apoptosis. Leuk Res 21: 37-43
41. Vogler WR, Olson AC, Okamoto S, Somberg LB, Glasser L (1987) Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplantation. Lipids 22: 919-924
42. Whitman SP, Civoli F, Daniel LW (1997) Protein kinase C β11 activation by 1-β-D-arabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl-2α down-regulation. J Biol Chem 272: 23481-23484
43. Winkler JD, Eris T, Sung CM, Chabot-Fletcher M, Mayer RJ, Surette ME, Chilton FH (1996) Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells. J Pharmacol Exp Ther 279: 956-966
44. Zhou X, Arthur G (1997) 1-O-octadecyl-2-O-methylglycerophosphocholine inhibits protein kinase C dependent phosphorylation of endogenous proteins in MCF-7 cells. Biochem J 324: 897-902